论文部分内容阅读
目的:探究重组人干扰素α2b联合一清胶囊治疗病毒性结膜炎的应用价值。方法:选择我院收治的病毒性结膜炎患者87例,随机分为联合组和对照组,分别进行重组人干扰素α2b联合一清胶囊和单纯重组人干扰素α2b治疗,对比两组临床疗效和临床相关指标变化。结果:联合组患者的临床治疗有效率、临床症状消失时间以及平均治愈时间均显著优于对照组患者,两者差别显著,具有统计学意义(P<0.05)。结论:重组人干扰素α2b联合一清胶囊有一定的协同作用,治疗病毒性结膜炎有显著的临床疗效,可以加快临床症状消失时间以及缩短治愈时间,有极大的临床价值。
Objective: To investigate the value of recombinant human interferon α2b combined with Yiqing capsule in the treatment of viral conjunctivitis. Methods: A total of 87 patients with viral conjunctivitis admitted to our hospital were randomly divided into combined group and control group. The patients were treated with recombinant interferon α 2b and Yi Qing capsule and recombinant interferon α 2b alone. The clinical efficacy and Changes in clinically relevant indicators. Results: The effective rate of clinical treatment, the disappearance of clinical symptoms and the average cure time in the combined group were significantly better than those in the control group. There was a significant difference between the two groups (P <0.05). CONCLUSION: Recombinant human interferon α2b combined with Yiqing Capsule has certain synergistic effect. It has significant clinical effect in treating viral conjunctivitis, accelerating the disappearance of clinical symptoms and shortening the healing time, and has great clinical value.